Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
56 hedge funds and large institutions have $1.02M invested in Navidea Biopharmaceuticals Inc. in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
8% more funds holding
Funds holding: 52 → 56 (+4)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
64% less capital invested
Capital invested by funds: $2.79M → $1.02M (-$1.77M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$13.1K |
| 2 |
CAG
Csenge Advisory Group
Clearwater,
Florida
|
+$8.24K |
| 3 |
Millennium Management
New York
|
+$4.04K |
| 4 |
SS
Simplicity Solutions
Minneapolis,
Minnesota
|
+$3.13K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$282K |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$180K |
| 3 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$55K |
| 4 |
Goldman Sachs
New York
|
-$31K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$20K |
NAVB Hedge Fund Activity: Q4 2018 in Review
56 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2018, worth a combined $1.02M — down 64% from $2.79M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NAVB positions and 6 closed out — a net gain of 4 holders — while 6 added to existing stakes and 7 trimmed.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $13.1K. The largest seller was Vanguard Group, cutting an estimated $282K.
- 56 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2018, up from 52 in Q3 2018.
- Funds reported $1.02M of Navidea Biopharmaceuticals Inc. stock for Q4 2018, down 64% quarter-over-quarter.
- 10 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2018 and 6 closed out, a net change of +4 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2018 was Two Sigma Securities, an estimated $13.1K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2018 was Vanguard Group, an estimated $282K sold.
Based on aggregated 13F filings for Q4 2018.